Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1297 is a small, non-coding RNA that functions as a gene expression regulator by binding to target mRNAs and suppressing their translation or promoting degradation. It has context-dependent roles in cancer, acting as a tumor suppressor in glioma, colorectal cancer, and hepatocellular carcinoma by inducing cell cycle arrest and apoptosis. Conversely, in some cancers, it can act as an oncogene by downregulating tumor suppressor genes such as PTEN and activating growth pathways. miR-1297 targets include HMGA1, PTEN, TRIB2, CCND2, COX2, MTDH, and others. Its expression profile and regulatory activity make it a promising biomarker and candidate target for therapeutic intervention, although clinical applications face challenges typical for microRNA-based therapies such as off-target effects and delivery issues.
Drugs or molecules that modulate miR-1297 typically act by either inhibiting its expression or restoring its function via mimics/antagomirs, leading to altered downstream gene expression (e.g., targeting HMGA1, PTEN, TRIB2, CCND2, COX2, MTDH)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1297 (miR-1297).